Prevention of N-methyl-N-nitrosourea-induced breast cancer by α-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8512-8520

  Parikh, Rahul R ^a   Gildener Leapman, Neil ^a   Narendran, Amithi ^a   Lin, Hung Yun ^b   Lemanski, Nicole ^a   Bennett, James A ^a   Jacobson, Herbert I ^a   Andersen, Thomas T ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN DERIVED PEPTIDE; ESTROGEN RECEPTOR; METHYLNITROSOUREA; NONAPEPTIDE; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CANCER PREVENTION; DERIVATIZATION; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ACTIVE SITE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ALKYLATING AGENTS; ALPHA-FETOPROTEINS; ANIMALS; BINDING SITES; FEMALE; HUMANS; INCIDENCE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MICE; MICE, SCID; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28544444611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1651     Document Type: Article

References (41)

1. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
2. Jordan VC, editor. Tamoxifen for the treatment and prevention of breast cancer. Melville (NY): PRR; 1999. p. 106-16.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
4. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995;49:241-57.
5. Fisher B, Costamino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
6. Jensen EV, DeSombre ER. Steroid hormone binding and hormone receptors. In: Holland JF, et al. editors. Cancer medicine. 1996. p. 1049-60.
7. Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:361-8.
8. Swanson SM, Whitaker LM, Stockard CR, et al. Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. Anticancer Res 1997;17: 4639-45.
9. Grubbs CJ, Hill DL, McDonough KC, Peckham JC. N-nitroso-N-methylurea- induced mammary carcinogenesis: effect of pregnancy on preneoplastic cells. J Natl Cancer Inst 1983;71:625-8.
10. Grubbs CJ, Juliana MM, Hill DL, Whitaker LM. Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland. Anticancer Res 1986;6:1395-400.
11. Jacobson HI, Thompson WD, Janerich DT. Multiple births and maternal risk of breast cancer. Am J Epidemiol 1989;129:865-73.
12. Morinaga T, Sakai M, Wegmann TG, Tamaoki T. Primary structures of human α-fetoprotein and its mRNA. Proc Natl Acad Sci U S A 1983;80:4604-8.
13. Crandall BF. α-Fetoprotein: a review. Crit Rev Clin Lab Sci 1981;15:127-85.
14. Jacobson HI, Janerich DT. Pregnancy-altered breast cancer risk: mediated by AFP? In: Mizejewski GJ, Jacobson HI, editors. Biological activities of α-fetoprotein. Volume 2. Boca Raton (FL): CRC Press; p. 93-100.
15. Richardson BE, Hulka BS, Peck JL, et al. Levels of maternal serum α-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 1998;148:719-27.
16. Sonnenschein C, Ucci AA, Soto AM. Growth inhibition of estrogen-sensitive rat mammary tumors. Effect of an α-fetoprotein-secreting hepatoma. J Natl Cancer Inst 1980;64:1147-52.
17. Bennett JA, Zhu S, Pagano-Mirarchi A, Kellom TA, Jacobson HI. α-Fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res 1998;4:2877-84.
18. Murgita RA, Tomasi TB, Jr. Suppression of the immune response by α-fetoprotein on the primary and secondary antibody response. J Exp Med 1975;141: 269-86.
19. Mesfin FB, Bennett JA, Jacobson HI, Zhu S, Andersen TT. α-Fetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta 2000;1501: 33-43.
20. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI. A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci U S A 2002;99:2211-5.
21. Mesfin FB, Andersen TT, Jacobson HI, Zhu S, Bennett JA. Development of a synthetic cyclized peptide derived from α-fetoprotein that prevents the growth of human breast cancer. J Pept Res 2001; 58:246-56.
22. DeFreest LA, Mesfin FB, Joseph L, et al. Synthetic peptide derived from α-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization. J Pept Res 2004; 63:409-19.
23. Kates SA, Daniels SB, Albericio F. Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides. Anal Biochem 1993;212:303-10.
24. Kates SA, Sole NA, Johnson CR, Hudson D, Baranay G, Albericia F. A novel, convenient, 3-dimensional orthogonal strategy for solid-phase synthesis of cyclic peptides. Tetrahedr Lett 1993;34:1549-52.
25. Grubbs CJ, Peckham JC, Cato KD. Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration. J Natl Cancer Inst 1983;70:209-12.
26. Grubbs CJ, Farnell DR, Hill DL, McDonough KC. Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17β-estradiol and progesterone. J Natl Cancer Inst 1985; 74:927-31.
27. Grubbs CJ, Steele VE, Casebolt T, et al. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 1995;15: 709-16.
28. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 1992;12:1147-53.
29. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
30. Cope MB, Steele VE, Eto I, Juliana MM, Hill DL, Grubbs CJ. Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3. Oncol Rep 2002;9:533-7.
31. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea- induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 1998; 58:921-6.
32. Zaizen Y, Higuchi Y, Matsuo N, Shirabe K, Tokuda H, Takeshita M. Antitumor effects of soybean hypocotyls and soybeans on the mammary tumor induction by N-methyl-N-nitrosourea in F344 rats. Anticancer Res 2000;20:1439-44.
33. Kotsopoulos J, Sohn KJ, Martin R, et al. Dietary folate deficiency suppresses N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Carcinogenesis 2003;24:937-44.
34. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci U S A 2001;98: 11755-9.
35. Russo IH, Koszalka M, Russo J. Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst 1990;82:1286-9.
36. Knott KK, McGinley JN, Lubet RA, Steele VE, Thompson HJ. Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea. Breast Cancer Res Treat 2001;70:171-83.
37. Christov K, Ikui A, Shilkaitis A, et al. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 2003;77: 253-64.
38. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor p-dependent apoptosis in breast cancer. Cancer Res 2004;64:3566-71.
39. Kang JS, Kim S, Che JH, Nam KT, Kim DJ, Jang DD, Yang KH. Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ. Oncol Rep 2004;12:689-93.
40. Swanson SM, Christov K. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor α status or Ha-ras mutation frequency. Anticancer Res 2003;23:3207-13.
41. Pei RJ, Sato M, Yuri T, Danbara N, Nikaido Y, Tsubura A. Effect of prenatal and prepubertal genistein exposure on N-methyl-N-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats. In Vivo 2003;17:349-57.